CN Patent

CN116801863A — 右美托咪定治疗方案

Assigned to Bioxcel Therapeutics Inc · Expires 2023-09-22 · 3y expired

What this patent protects

本文公开向人受试者施用右美托咪定或其药学上可接受的盐的方法。所公开的方法特别适于治疗躁动，尤其是当与神经变性和/或神经精神疾病或病症(诸如痴呆和谵妄)相关的时候。

USPTO Abstract

本文公开向人受试者施用右美托咪定或其药学上可接受的盐的方法。所公开的方法特别适于治疗躁动，尤其是当与神经变性和/或神经精神疾病或病症(诸如痴呆和谵妄)相关的时候。

Drugs covered by this patent

chembl-chembl2106195 (DEXMEDETOMIDINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN116801863A
Jurisdiction: CN
Classification: —
Expires: 2023-09-22
Drug substance claim: No
Drug product claim: No
Assignee: Bioxcel Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.